Blockade of invariant TCR-CD1D interaction specifically inhibits antibody production against blood group a carbohydrates

Blood

Volumn 122, Issue 15, 2013, Pages 2582-2590

  Tazawa, Hirofumi ^a   Irei, Toshimitsu ^a   Tanaka, Yuka ^a   Igarashi, Yuka ^a   Tashiro, Hirotaka ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; CD1D ANTIGEN; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD1D; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BLOOD GROUP A; BLOOD GROUP O; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENGRAFTMENT; ERYTHROCYTE; HUMAN; HUMAN CELL; IMMUNIZATION; INHIBITION KINETICS; MOLECULAR INTERACTION; MOUSE; NATURAL KILLER T CELL; NOD SCID MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR BLOCKING; WILD TYPE;

EID: 84888224690     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-407452     Document Type: Article

References (45)

1. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23:877-900.
2. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483-513.
3. Kawano T, Cui J, Koezuka Y, et al. CD1drestricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278(5343):1626-1629.
4. Carnaud C, Lee D, Donnars O, et al. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163(9):4647-4650.
5. Singh N, Hong S, Scherer DC, et al. Cutting edge: activation of NK T cells by CD1d and alphagalactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol. 1999;163(5):2373-2377.
6. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alphagalactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198(2):267-279.
7. Kitamura H, Ohta A, Sekimoto M, et al. Alphagalactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol. 2000;199(1):37-42.
8. Lang GA, Exley MA, Lang ML. The CD1d-binding glycolipid alpha-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology. 2006;119(1):116-125.
9. Galli G, Nuti S, Tavarini S, et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med. 2003;197(8):1051-1057.
10. Schofield L, McConville MJ, Hansen D, et al. CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science. 1999;283(5399):225-229.
11. Lang GA, Devera TS, Lang ML. Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood. 2008;111(4):2158- 2162.
12. Yang JQ, Wen X, Kim PJ, Singh RR. Invariant NKT cells inhibit autoreactive B cells in a contactand CD1d-dependent manner. J Immunol. 2011;186(3):1512-1520.
13. Zhou W, Ohdan H, Asahara T. Calcineurin inhibitors block B-1 cell differentiation: the relevance to immunosuppressive treatment in ABO-incompatible transplantation. Transplant Proc. 2005;37(4):1808-1811.
14. Irei T, Ohdan H, Zhou W, et al. The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. Blood. 2007;110(13):4567-4575.
15. Ohdan H, Swenson KG, KrugerGray HS, et al. Mac-1-negative B-1b phenotype of natural antibodyproducing cells, including those responding to Gal alpha 1, 3Gal epitopes in alpha 1, 3-galactosyltransferase-deficient mice. J Immunol. 2000;165(10):5518-5529.
16. Tahara H, Ide K, Basnet NB, et al. Immunological property of antibodies against N-glycolylneuraminic acid epitopes in cytidine monophospho-N- acetylneuraminic acid hydroxylase-deficient mice. J Immunol. 2010;184(6):3269-3275.
17. Naito Y, Takematsu H, Koyama S, et al. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol Cell Biol. 2007;27(8):3008-3022.
18. Harada M, Seino K, Wakao H, et al. Downregulation of the invariant Valpha14 antigen receptor in NKT cells upon activation. Int Immunol. 2004;16(2):241-247.
19. Tanemura M, Ogawa H, Yin DP, Chen ZC, DiSesa VJ, Galili U. Elimination of anti-Gal B cells by alpha-Gal ricin1. Transplantation. 2002;73(12):1859-1868.
20. Venkataswamy MM, Porcelli SA. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol. 2010;22(2):68-78.
21. Gansert JL, Kiessler V, Engele M, et al. Human NKT cells express granulysin and exhibit antimycobacterial activity. J Immunol. 2003;170(6):3154-3161.
22. Zhou W, Ohdan H, Tanaka Y, et al. NOD/SCID mice engrafted with human peripheral blood lymphocytes can be a model for investigating B cells responding to blood group A carbohydrate determinant. Transpl Immunol. 2003;12(1):9-18.
23. Ohdan H, Yang YG, Shimizu A, Swenson KG, Sykes M. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1, 3Gal-mediated graft rejection. J Clin Invest. 1999;104(3):281-290.
24. Pellicci DG, Hammond KJ, Uldrich AP, Baxter AG, Smyth MJ, Godfrey DI. A natural killer T (NKT) cell developmental pathway involving a thymusdependent NK1.1 (-) CD4 (+) CD1d-dependent precursor stage. J Exp Med. 2002;195(7):835-844.
25. Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an alphagalactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998;188(8):1521-1528.
26. Kinjo Y, Tupin E, Wu D, et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol. 2006;7(9):978-986.
27. Kinjo Y, Wu D, Kim G, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature. 2005;434(7032):520-525.
28. Mattner J, Debord KL, Ismail N, et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature. 2005;434(7032):525-529.
29. Paget C, Mallevaey T, Speak AO, et al. Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids. Immunity. 2007;27(4):597-609.
30. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol. 2003;4(12):1230-1237.
31. Kinjo Y, Illarionov P, Vela JL, et al. Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol. 2011;12(10):966-974.
32. Brennan PJ, Tatituri RV, Brigl M, et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol. 2011;12(12):1202-1211.
33. Zhou D, Mattner J, Cantu C III, et al. Lysosomal glycosphingolipid recognition by NKT cells. Science. 2004;306(5702):1786-1789.
34. Pellicci DG, Clarke AJ, Patel O, et al. Recognition of β-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol. 2011;12(9):827-833.
35. Christiansen D, Vaughan HA, Milland J, et al. Antibody responses to glycolipid-borne carbohydrates require CD4+ T cells but not CD1 or NKT cells. Immunol Cell Biol. 2011;89(4):502-510.
36. Marquina G, Waki H, Fernandez LE, et al. Gangliosides expressed in human breast cancer. Cancer Res. 1996;56(22):5165-5171.
37. Miyake M, Hashimoto K, Ito M, et al. The abnormal occurrence and the differentiationdependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumors. A study with specific monoclonal antibodies. Cancer. 1990;65(3):499-505.
38. Deguchi T, Tanemura M, Miyoshi E, et al. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Res. 2010;70(13):5259-5269.
39. Abdel-Motal UM, Wigglesworth K, Galili U. Intratumoral injection of alpha-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother. 2009;58(10):1545-1556.
40. Hanisch FG, Hacker J, Schroten H. Specificity of S fimbriae on recombinant Escherichia coli: preferential binding to gangliosides expressing NeuGc alpha (2-3) Gal and NeuAc alpha (2-8) NeuAc. Infect Immun. 1993;61(5):2108-2115.
41. Vink A, Warnier G, Brombacher F, Renauld JC. Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J Exp Med. 1999;189(9):1413- 1423.
42. Yoshida T, Ikuta K, Sugaya H, et al. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alphadeficient mice. Immunity. 1996;4(5):483-494.
43. Nisitani S, Tsubata T, Murakami M, Honjo T. Administration of interleukin-5 or -10 activates peritoneal B-1 cells and induces autoimmune hemolytic anemia in anti-erythrocyte autoantibody-transgenic mice. Eur J Immunol. 1995;25(11):3047-3052.
44. King IL, Fortier A, Tighe M, et al. Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner. Nat Immunol. 2012;13(1):44-50.
45. Kantor AB, Merrill CE, Herzenberg LA, Hillson JL. An unbiased analysis of V (H)-D-J (H) sequences from B-1a, B-1b, and conventional B cells. J Immunol. 1997;158(3):1175-1186.